RAAS inhibition in heart failure: Corner stone of therapy & potassium homeostasis

10' education - May 23, 2016 - ESC HF 2016, Florence, Italy - Faiez Zannad, MD - CHU- Nancy University Nancy, France

Video navigation menu

Class 1A guideline recommendations are not followed well in clinical practice 0:29
What are the consequences if HF patients are not on optimal therapy? 3:25
Hyperkalemia is an inherent risk of RAAS inhibiting treatment, but does not elimate its benefit 6:19
Hyperkalemia can be prevented if monitoring frequently as per recommendations. 9:32
How may the new potassium binders be of benefit to optimise RAAS inhibitory therapy? 11:10
Summary 13:17

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.